Government watchdog finds that most but not all generic drug prices are falling

Government watchdog finds that most but not all generic drug prices are falling

A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.

Report: 3 tips for pharma to provide beyond-the-pill services

Report: 3 tips for pharma to provide beyond-the-pill services

Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.

Five things for pharma marketers to know: Wednesday, July 27, 2016

Five things for pharma marketers to know: Wednesday, July 27, 2016

IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

No free lunch for docs: Sponsored meals linked to more prescriptions

No free lunch for docs: Sponsored meals linked to more prescriptions

A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.

Panel: Why data is the first step in telling a human story

Panel: Why data is the first step in telling a human story

The ability to pair data with a story or a human emotion is often easier for women.

The CIO, reimagined for pharma

The CIO, reimagined for pharma

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Pharma is reluctant to adopt digital in R&D: survey

Pharma is reluctant to adopt digital in R&D: survey

Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Conflicting polls highlight uncertainty about the public's opinion of pharma

Conflicting polls highlight uncertainty about the public's opinion of pharma

Two recent polls paint a complicated picture of the public's opinion of the pharma industry.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Ponemon: Cybercrime is top cause for healthcare data breaches

Ponemon: Cybercrime is top cause for healthcare data breaches

A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.